Coccidioidomycosis Drug Market Report 2026

The coccidioidomycosis drug market size has grown strongly in recent years. It will grow from $0.35 billion in 2025 to $0.38 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing fungal infection incidence, widespread fluconazole usage, expansion of infectious disease clinics, improved diagnostic testing, rising immunocompromised population.

The coccidioidomycosis drug market size is expected to see strong growth in the next few years. It will grow to $0.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to climate-related disease spread, rising awareness of valley fever, growth in antifungal drug development, expansion of specialty clinics, increasing healthcare access. Major trends in the forecast period include rising use of azole antifungal therapies, increasing focus on long-term antifungal treatment, growing diagnosis in endemic regions, expansion of hospital-based infectious disease care, increased attention to immunocompromised patients.

The rising number of immunocompromised individuals is expected to drive the growth of the coccidioidomycosis drug market in the coming years. Immunocompromised individuals are those with weakened immune systems, making them more vulnerable to infections and illnesses, including those affected by human immunodeficiency virus (HIV), cancer, or prior organ transplants. The immunocompromised population is increasing due to factors such as the growing prevalence of chronic diseases, higher numbers of organ transplants, widespread use of immunosuppressive therapies, and the rising incidence of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Coccidioidomycosis drugs assist immunocompromised patients by controlling fungal infections, reducing disease severity, and preventing complications like disseminated coccidioidomycosis, which can be life-threatening due to their weakened immune response. For example, in July 2024, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based United Nations organization, around 39.9 million people were living with HIV in 2023, up from 39 million in 2022. Thus, the growing number of immunocompromised individuals is fueling the expansion of the coccidioidomycosis drug market.

Major companies operating in the coccidioidomycosis drug market are emphasizing renewed R&D investments in innovative antifungal therapies and vaccines, including chitin synthase inhibitors and next-generation systemic agents, to address rising incidence and drug resistance. A chitin synthase inhibitor is a therapeutic compound that targets fungal chitin synthase enzymes, disrupting fungal cell wall formation and reducing the survival of Coccidioides species. For example, in June 2025, Valley Fever Solutions, a US-based biotech firm, progressed NikZ (Nikkomycin Z) into Phase I/II trials; the drug offers inhalable delivery, strong chitin synthase inhibition against both acute and chronic infections, and orphan drug designations, aiming for enhanced efficacy with shorter treatment courses. Additional backing comes from government agencies: the U.S. National Institute of Allergy and Infectious Diseases (NIAID), through its 2025 Valley Fever Strategic Plan, continues to support clinical trial infrastructure, vaccine research, and antifungal innovation.

In November 2023, Basilea Pharmaceutica Ltd., a Switzerland-based biopharmaceutical firm, acquired the rights to fosmanogepix from Amplyx Pharmaceuticals Inc. for an undisclosed sum. Through this acquisition, Basilea intends to commence the first phase III study of fosmanogepix in 2024, strengthening its presence in the antifungal treatment sector and addressing the critical demand for new antifungal therapies. Amplyx Pharmaceuticals Inc. is a US-based pharmaceutical company and an affiliate of Pfizer Inc. that focuses on developing drugs for infectious diseases, including coccidioidomycosis.

Major companies operating in the coccidioidomycosis drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Viatris Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited, Dr. Reddy's Laboratories, Zydus Group, Amneal Pharmaceuticals Inc., Recordati S.p.A., Glenmark Pharmaceuticals Limited, Xellia Pharmaceuticals Pvt. Ltd., Brundavan laboratories Pvt.Ltd., LGM Pharma, Enomark Pharma.

North America was the largest region in the coccidioidomycosis drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coccidioidomycosis drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coccidioidomycosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported antifungal APIs and finished formulations used in the production of azole based therapies. The impact is strongest in azole drug segments, where manufacturing scale and pricing sensitivity are high. Regions such as North America have experienced higher input costs due to reliance on cross border pharmaceutical sourcing. Rising tariff related expenses have influenced production economics, pricing strategies, and procurement planning for antifungal treatments. Tariffs have supported local pharmaceutical manufacturing, expanded domestic production capacity, and strengthened regional drug supply chains over the long term.

The coccidioidomycosis drug market research report is one of a series of new reports that provides coccidioidomycosis drug market statistics, including coccidioidomycosis drug industry global market size, regional shares, competitors with a coccidioidomycosis drug market share, detailed coccidioidomycosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the coccidioidomycosis drug industry. This coccidioidomycosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A coccidioidomycosis drug is a medication developed to treat infections caused by Coccidioides species, the fungi that lead to valley fever. These drugs, including azole antifungals and polyene antifungals, work to inhibit fungal growth and alleviate symptoms. Depending on the infection’s severity, treatment may be administered orally, intravenously, or over a prolonged period to prevent complications, particularly in immunocompromised individuals.

The primary categories of drugs for treating coccidioidomycosis include azoles, echinocandins, and polyenes. Azoles are a group of antifungal medications that work by blocking the production of ergosterol, a vital component of fungal cell membranes. Treatment can be administered through oral or intravenous routes, with specific phases including the acute phase, chronic phase, and preventive therapy. Patients are classified as either immunocompetent or immunocompromised, while end-users consist of specialty clinics, hospitals, homecare services, and other care settings.

The coccidioidomycosis drug market consists of revenues earned by entities by providing services such as diagnostic testing, patient management programs, pharmacovigilance services, drug consultation and advisory, clinical trials for new treatments, and education and awareness campaigns aimed at improving diagnosis, treatment adherence and overall patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The coccidioidomycosis drug market also includes sales of antifungal medications and other treatment options, along with diagnostic kits, treatment formulations, intravenous therapies, and combination drug therapies designed to manage and treat valley fever and related complications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.